The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents

John H. Kwon, Richard J. Farrell

Research output: Contribution to journalReview article

46 Citations (Scopus)

Abstract

Immunosuppressive agents have become an established part of the therapeutic armamentarium for inflammatory bowel disease (IBD). However, when used in transplant recipients or for other indications, agents that suppress or modulate the immune system (immunomodulators) have been associated with an increased risk of lymphoma. Fortunately, in part because of the lower doses used in IBD patients, the risk of lymphoma in IBD patients appears to be significantly less than that associated with renal and hepatic transplant-related immunosuppression. Whether the risk of azathioprine or 6-mercaptopurine associated lymphoma in IBD is real or relates to the underlying disease remains unclear. The results of several recent large well designed population-based studies suggest that the lymphoma risk associated with azathioprine and 6-mercaptopurine therapy is likely to be of minimal clinical significance compared to the established and more frequent risks of myelosuppression and infection, and is far outweighed by the clinical benefit of immunomodulator therapy in IBD. While the issue of lymphoma risk is likely to become more relevant with the growing number of biologic and immunomodulators being tested in clinical trials for IBD, early post-marketing surveillance data on infliximab suggests that the lymphoma risk may not be any greater than that associated with azathioprine and 6-mercaptopurine.

Original languageEnglish (US)
Pages (from-to)169-178
Number of pages10
JournalCritical Reviews in Oncology/Hematology
Volume56
Issue number1 SPEC. ISS.
DOIs
StatePublished - Oct 1 2005

Fingerprint

Immunosuppressive Agents
Inflammatory Bowel Diseases
Lymphoma
6-Mercaptopurine
Azathioprine
Immunologic Factors
Therapeutics
Marketing
Immunosuppression
Immune System
Clinical Trials
Transplants
Kidney
Liver
Infection
Population

Keywords

  • Immunomodulators
  • Inflammatory bowel disease
  • Lymphoma
  • Myelosuppression

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents. / Kwon, John H.; Farrell, Richard J.

In: Critical Reviews in Oncology/Hematology, Vol. 56, No. 1 SPEC. ISS., 01.10.2005, p. 169-178.

Research output: Contribution to journalReview article

Kwon, John H. ; Farrell, Richard J. / The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents. In: Critical Reviews in Oncology/Hematology. 2005 ; Vol. 56, No. 1 SPEC. ISS. pp. 169-178.
@article{3986a05bbd0449c3b1076ae83a9b6cc9,
title = "The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents",
abstract = "Immunosuppressive agents have become an established part of the therapeutic armamentarium for inflammatory bowel disease (IBD). However, when used in transplant recipients or for other indications, agents that suppress or modulate the immune system (immunomodulators) have been associated with an increased risk of lymphoma. Fortunately, in part because of the lower doses used in IBD patients, the risk of lymphoma in IBD patients appears to be significantly less than that associated with renal and hepatic transplant-related immunosuppression. Whether the risk of azathioprine or 6-mercaptopurine associated lymphoma in IBD is real or relates to the underlying disease remains unclear. The results of several recent large well designed population-based studies suggest that the lymphoma risk associated with azathioprine and 6-mercaptopurine therapy is likely to be of minimal clinical significance compared to the established and more frequent risks of myelosuppression and infection, and is far outweighed by the clinical benefit of immunomodulator therapy in IBD. While the issue of lymphoma risk is likely to become more relevant with the growing number of biologic and immunomodulators being tested in clinical trials for IBD, early post-marketing surveillance data on infliximab suggests that the lymphoma risk may not be any greater than that associated with azathioprine and 6-mercaptopurine.",
keywords = "Immunomodulators, Inflammatory bowel disease, Lymphoma, Myelosuppression",
author = "Kwon, {John H.} and Farrell, {Richard J.}",
year = "2005",
month = "10",
day = "1",
doi = "10.1016/j.critrevonc.2005.02.004",
language = "English (US)",
volume = "56",
pages = "169--178",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "1 SPEC. ISS.",

}

TY - JOUR

T1 - The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents

AU - Kwon, John H.

AU - Farrell, Richard J.

PY - 2005/10/1

Y1 - 2005/10/1

N2 - Immunosuppressive agents have become an established part of the therapeutic armamentarium for inflammatory bowel disease (IBD). However, when used in transplant recipients or for other indications, agents that suppress or modulate the immune system (immunomodulators) have been associated with an increased risk of lymphoma. Fortunately, in part because of the lower doses used in IBD patients, the risk of lymphoma in IBD patients appears to be significantly less than that associated with renal and hepatic transplant-related immunosuppression. Whether the risk of azathioprine or 6-mercaptopurine associated lymphoma in IBD is real or relates to the underlying disease remains unclear. The results of several recent large well designed population-based studies suggest that the lymphoma risk associated with azathioprine and 6-mercaptopurine therapy is likely to be of minimal clinical significance compared to the established and more frequent risks of myelosuppression and infection, and is far outweighed by the clinical benefit of immunomodulator therapy in IBD. While the issue of lymphoma risk is likely to become more relevant with the growing number of biologic and immunomodulators being tested in clinical trials for IBD, early post-marketing surveillance data on infliximab suggests that the lymphoma risk may not be any greater than that associated with azathioprine and 6-mercaptopurine.

AB - Immunosuppressive agents have become an established part of the therapeutic armamentarium for inflammatory bowel disease (IBD). However, when used in transplant recipients or for other indications, agents that suppress or modulate the immune system (immunomodulators) have been associated with an increased risk of lymphoma. Fortunately, in part because of the lower doses used in IBD patients, the risk of lymphoma in IBD patients appears to be significantly less than that associated with renal and hepatic transplant-related immunosuppression. Whether the risk of azathioprine or 6-mercaptopurine associated lymphoma in IBD is real or relates to the underlying disease remains unclear. The results of several recent large well designed population-based studies suggest that the lymphoma risk associated with azathioprine and 6-mercaptopurine therapy is likely to be of minimal clinical significance compared to the established and more frequent risks of myelosuppression and infection, and is far outweighed by the clinical benefit of immunomodulator therapy in IBD. While the issue of lymphoma risk is likely to become more relevant with the growing number of biologic and immunomodulators being tested in clinical trials for IBD, early post-marketing surveillance data on infliximab suggests that the lymphoma risk may not be any greater than that associated with azathioprine and 6-mercaptopurine.

KW - Immunomodulators

KW - Inflammatory bowel disease

KW - Lymphoma

KW - Myelosuppression

UR - http://www.scopus.com/inward/record.url?scp=24644495220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24644495220&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2005.02.004

DO - 10.1016/j.critrevonc.2005.02.004

M3 - Review article

C2 - 15979323

AN - SCOPUS:24644495220

VL - 56

SP - 169

EP - 178

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 1 SPEC. ISS.

ER -